GlassScriptPhysician profile
David J Kaplan
NPI 1932349784
$2,030.15
in general payments reported to CMS, 2019-2025
26 companies · $531 in 2025
The $531 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $467 · 2020: $219 · 2021: $286 · 2022: $93.75 · 2023: $99.57 · 2024: $334 · 2025: $531.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $964.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $964.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $435.81 | 2019-2022 | |
| Laborie Medical Technologies Corp. | $199.68 | 2023-2024 | Optilume Bph Drug Coated Balloon Catheter |
| Abbvie INC. | $181.42 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $127.46 | 2024-2025 | |
| Procept Biorobotics Corporation | $118.39 | 2023-2025 | Aquabeam Robotic System, Aquabeam System |
| Smith+Nephew, INC. | $117.23 | 2019 | |
| Biotissue Holdings INC. | $109.10 | 2021 | |
| Varian Medical Systems, INC. | $102.99 | 2020 | |
| Calyxo, INC. | $92.23 | 2025 | Cvac Aspiration System |
| Medtronic, INC. | $77.40 | 2021 | |
| Progenics Pharmaceuticals, INC. | $52.09 | 2024 | |
| Ferring Pharmaceuticals INC. | $46.20 | 2025 | Adstiladrin |
| Endo USA, INC. | $45.73 | 2025 | Xiaflex, Aveed |
| Olympus America INC. | $45.60 | 2023-2025 | Itind System |
| Baxter Healthcare | $40.08 | 2025 | Floseal |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $39.26 | 2021-2024 | |
| Urogen Pharma, INC. | $37.06 | 2021-2022 | |
| Neotract INC. | $28.57 | 2019 | |
| Pfizer INC. | $26.28 | 2025 | |
| Teleflex LLC | $25.50 | 2024 | Urolift |
| Allergan, INC. | $18.16 | 2020 | |
| Sun Pharmaceutical Industries INC. | $17.96 | 2021 | |
| Profound Medical Corp. | $16.21 | 2023 | Tulsa-Pro |
| Tolmar Pharmaceuticals, INC. | $15.70 | 2021 | |
| Endo Pharmaceuticals INC. | $14.04 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kaplan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.